Category: Biomedical Logo
Posted Jul 2, 2019 12:04 (GMT +7)

Terns Pharmaceuticals Appoints Ankang Li Ph.D. J.D. CFA as Chief Financial Officer


Terns Pharmaceuticals, Inc., a global biopharmaceutical company focused on discovering and developing innovative therapies to treat non-alcoholic steatohepatitis (NASH) and cancer, announced today the appointment of Ankang Li, Ph.D., J.D., CFA as Chief Financial Officer.

This press release features multimedia. View the full release here:

Ankang Li, Chief Financial Officer (Photo: Business Wire)

Ankang Li, Chief Financial Officer (Photo: Business Wire)

“Dr. Li joins Terns with over 10 years of experience in investment banking, business development, legal advisory, and biomedical research,” said Weidong Zhong, Ph.D., President and CEO of Terns. “We are pleased to welcome Dr. Li to Terns. He has a strong record of driving growth in the biopharma industry.”

At Terns, Dr. Li will be responsible for corporate financing, financial reporting, accounting, risk management, business development, and investor relations.

Prior to joining Terns, Dr. Li was the Executive Director of Healthcare Investment Banking at Goldman Sachs, where he was responsible for Asia ex-Japan investment banking and led many high-profile IPOs for biotechnology and other healthcare clients. Before that, Dr. Li was a Director at the Asia Pacific Innovation Hub at Merck (known as MSD outside the U.S. and Canada), overseeing business development and licensing transactions in the region. Dr. Li also worked at both Davis Polk and Ropes & Gray, advising clients on capital markets and M&A transactions. Early in his career, he conducted biomedical research at the Salk Institute.

Ankang Li received a Juris Doctor degree from The University of Chicago Law School, a Ph.D. in Biomedical Sciences from Baylor College of Medicine, a Master of Science degree in Biological Sciences from the National University of Singapore, and a Bachelor of Science degree in Biochemistry from Fudan University. He is a CFA charter holder.

“Terns has emerged as one of the leading biopharmaceutical companies developing therapeutics for liver disease,” commented Dr. Li. “I look forward to working with Terns’ board and the leadership team to help advance their innovative pipeline and programs to benefit patients in China and worldwide.”

About Terns Pharmaceuticals

Terns Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company that is focused on the discovery and development of medicines for chronic liver disease and cancer. Based in China and the United States, the company is advancing a pipeline of drug candidates for the treatment of non-alcoholic steatohepatitis (NASH) and cancer, across multiple modalities. Terns leverages world class expertise in disease biology, medicinal chemistry, and clinical development in order to bring promising new therapies to patients in China and other global markets.

View source version on

US Media Contact:
Margaret Robinson
+1 (415) 690 0084

China Media Contact:
Yan Wan
+86 186 1196 5371

Distribute your news release with us

  • Print

    unique advertising solution

    Our media lists include news desks at all leading Thai and English-language dailies.

  • Radio & TV

    reliable platform

    We deliver your news to leading Thai radio stations and TV channels.

  • Internet Sites

    cloud computing

    All releases are submitted to Internet news sites, including several with guaranteed pickup.

Our Self-Serve News Release Couldn't Be Simpler

Our streamlined online process makes it simple and fast to submit your news to the Thai media. Once registered, just enter or copy your text into our submission form and you'll see an instant preview with our fee based on the word count, translation, and any attached image. To confirm submission, hit Enter to be taken to our payment processor. Once payment is approved, your release passes automatically to our news desk for translation and dissemination by our skilled and experienced team. You'll be kept informed at each step of the process.